null

null

null

null

null

null

null

null

null

1.06x Total Debt / Equity (Elevated leverage)

Low direct sensitivity; debt-free clinical-stage biotech funded by equity raises, but rising rates increase cost of future capital raises and compress biotech valuations

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API active pharmaceutical ingredients sourced from contract manufacturers in China/India; 2) specialized biologics CMOs concentrated in Western Europe and North America

Pre-revenue clinical stage; no meaningful international commercial revenue, so sovereign currency devaluation exposure is negligible currently

Operations primarily US-based (San Diego HQ) with clinical trial sites in Europe and Israel; minimal currency revenue exposure as company is pre-commercial

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CMO partners for XPro1595 and LM11A-31 supply; no substitutable second-source exists without 12-18 month qualification delay

Clinical-stage biotech; cloud disruption would cause operational friction but not existential risk; core IP and trial data stored in regulated systems

Secondary infrastructure risk is moderate; CRO platforms and electronic data capture (EDC) systems have greater lock-in than cloud provider itself

Moderate API coupling risk via EDC vendors (Medidata/Veeva); switching mid-trial would require FDA notification and could invalidate data integrity

Low Howey risk; INMB is a traditional equity security, revenue model is pharmaceutical licensing/milestone-based, not a tokenized instrument

Very High

Moderate GDPR exposure from EU clinical trial patient data; CCPA applies to limited California-based subjects; compliance frameworks standard for IND-stage biotech

Negligible antitrust risk; pre-revenue niche CNS/neuroinflammation biotech with no market share to defend or pricing power to scrutinize

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring revenue currently; 100% transactional/milestone-based future model via licensing deals, partnership payments, and eventual product royalties

Primary monetization via pharma partnership licensing fees, regulatory milestone payments, and long-term royalties on approved neuroinflammation drugs

No commercial pricing architecture yet; future pricing will follow CNS biologics comps (~$50K-$150K/year per patient) subject to payer negotiation

Moderate-to-high potential pricing power if approved; addresses unmet need in Alzheimer's neuroinflammation with no direct approved competitor in TNF modulation

Pharma royalty/licensing model targets 80-90% gross margins at commercialization; current gross margin is negative (R&D spend only)

No free-rider leakage applicable; IP-protected pipeline with patents on XPro1595 and LM11A-31; no open-source or generic substitution risk near-term

Revenue growth is sublinear to headcount; milestone and royalty income scales without proportional headcount; current ~20 FTE structure is lean virtual model

Near-zero marginal cost of royalty/licensing revenue at scale; clinical-stage cost is fixed-trial-driven, not volume-driven

Not applicable; Inmune Bio is not a franchise business model

At 10x scale (post-approval), CAC is negligible vs. LTV; pharma partnerships replace direct customer acquisition; payer access teams are primary cost

No traditional network effects; scientific data network effect exists as biomarker platform (Alzheimer's patient stratification) becomes more valuable with more trial data

142.0% Return on Assets (Outstanding)

Moderate recession resilience; NIH/government grant funding partially insulates, but equity capital markets for biotech are highly recession-sensitive

Pharmaceutical/biotech partners and licensees as B2B customers; high concentration risk as single partnership deal could represent 80%+ of near-term revenue

Government and foundation grant bodies (NIH, Alzheimer's Association) as secondary non-dilutive funding segment; reduces but does not eliminate concentration risk

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

2084.0% CapEx / Revenue (High-CapEx Infrastructure)

0001711754

INMB